Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Agilent's Opdivo CDx Gets Expanded CE Mark in Europe

Agilent's Opdivo CDx Gets Expanded CE Mark in Europe

Jun 16, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Agilent Technologies announced today that its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab), has has received an expanded CE mark for use in Europe.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. BARDA Exercises $10.5M Option on T2 Bio Contract

  2. Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

  3. PerkinElmer Newborn Screening Assay Receives CE-IVD Mark

  4. Access Genetics Nabs Amended FDA Emergency Use Authorization for Oral Rinse SARS-CoV-2 PCR Test

  5. Inflammatix Receives $1.1M DARPA Award to Develop Predictive COVID-19 Diagnostic

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.